Category: ACN Newswire

香港, 2025年4月2日 - (亞太商訊 via SeaPRwire.com) - 3月29日，《周遊記3》正式在浙江衛視、Z視介、優酷同步上線。首期節目鎖定在浪漫愛琴海之濱的雅典。本季「全民健身教練」劉畊宏也正式加入「周遊團」，異國街頭帶練「本草綱目」。開播當日，《周遊記3》即以破竹之勢斬獲優酷熱度榜第一，並拿下CSM71城省級衛視同時段收視冠軍，全網相關話題曝光量近2億，熱搜狂攬22個，微博、抖音、小紅書熱度飆升，強勢開啟「周遊」新篇章。節目開播恰逢周杰倫「嘉年華」演唱會三亞站，周杰倫本人在演唱會現場喊話粉絲要去看《周遊記3》，並在自己的社交平台上喊話粉絲分享最有趣的片段。節目第一期完播後，周杰倫曬出節目取得的成績，用滿屏「開心」向粉絲分享自己的喜悅。《周遊記3》首期節目通過街頭鬥舞、即興音樂創作等環節，巧妙融合希臘文化探索與明星互動趣味，再度印證節目背後打造者巨星傳奇的頂流IP運營實力。本季節目由魔胴西西里咖啡（MODONG MAGIC）獨家冠名，支付寶擔任戰略合作，ADATA、恩雅賽博吉他、愛吃鮮摩人、VIVICYCLE特約贊助，多元品牌強勢入駐，彰顯頂流內容IP的商業價值。值得注意的是，魔胴、愛吃鮮摩人、VIVICYCLE是巨星傳奇新零售業務的明星品牌。魔胴咖啡是巨星傳奇的王牌產品，2025年魔胴咖啡進行品牌升級，推出全新MODONG MAGIC系列新品 - 魔胴西西里咖啡·檸檬風味咖啡&魔胴仙人掌風味黑咖啡，強調「隨身一杯·打造健康生活魔法家」的品牌概念。據灼識諮詢報告，按總商品交易額（GMV）計，魔胴咖啡於2020-2024年連續五年蟬聯中國防彈飲料市佔率第一。愛吃鮮摩人是劉畊宏Vivi夫婦聯手打造的健康生活方式品牌，強調乾淨配料表理念，推出了一系列健康至上、配料表乾淨、無防腐劑的健康創新食品。根據灼識諮詢統計，按總商品交易額（GMV）計，愛吃鮮摩人抹茶粉在2022年推出後，於2023年成為抖音天然粉賽道市場份額第一的產品。VIVICYCLE是以Vivi為主理人的輕運動生活方式品牌，專注於輕運動生活場景需求，打造當下最流行的輕運動生活方式。區別於藝人經紀公司，巨星傳奇致力於圍繞不同藝人的特性塑造自有品牌，對於明星IP的商業價值開發也堅持長線開發思路。在本季節目背後，巨星傳奇憑藉精品內容IP實現商業閉環再升級。業內人士指出：《周遊記》背後的商業邏輯是巨星傳奇通過《周遊記》吸引到品牌贊助及實現節目版權收入的同時，節目亦可以賦能自有IP及品牌以帶動新零售產品的銷售，依靠藝人的影響力及直播電商、私域等全域渠道推廣產品，將IP的流量轉化為產品的銷量，形成了完整的「IP賦能新零售」的商業化閉環，充分體現了其運營模式的優越性。此次《周遊記3》開播即爆，不僅為巨星傳奇IP版圖再添里程碑，更彰顯其運營模式的可複製性與長效生命力。此前，這一模式就已經得到了市場的充分認證。從2020年的「魔幻之旅」，到2023年的「樂遊世界」，走過兩季的《周遊記》憑藉無腳本、無人設、無規則的真實質感不僅收穫眾多好評，也從內容IP為新零售產品帶來了諸多賦能。如在《周遊記1》中頻繁露出魔胴咖啡，就在節目播出的2020年實現了上市一年內銷售額同比增長超360%的商業奇蹟，帶動巨星傳奇當年的淨利潤同比增長了233.04%。相比第一季，《周遊記2》收視率更邁上了更高的台階，節目播出首集即創下同時段收視率第一位，相關話題在微博閱讀量已突破6億，全網收穫超過390個熱搜，快手全站播放量超25.2億，市場反響熱烈，對巨星傳奇旗下新零售產品銷售帶來了更為顯著的驅動力。除《周遊記》外，巨星傳奇為庾澄慶打造的音樂訪談秀節目《樂來樂快樂》也在播出後收穫了極高人氣，創下同時段同類綜藝節目的最高收視率。節目全網收穫超過200個熱搜，熱搜話題在榜時長超過900小時，相關話題全網閱讀量超20億，引爆話題討論。根據巨星傳奇2024年財報，公司全年實現總收入5.84億元，同比增長35.8%；毛利3.27億元，同比增加約18.4%；淨利潤5024萬元，同比增加約21.3%。在IP創造及營運與新零售兩大業務協同發力下，公司連續實現收入與利潤雙增長。2024財年公司電視節目播出產生收入達人民幣1.68億元，使得IP創造及營運業務以3.14億元收入創歷史新高，同比大幅增長65.1%，收入佔比從2023年的44.2%躍升至53.8%。新零售業務收入2.70億元，同比增長約12.5%。如此亮眼的業績反映了IP生態持續帶來的收入增長，也彰顯出巨星傳奇在IP打造與IP賦能新零售領域強大的複製能力。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月31日 - (亞太商訊 via SeaPRwire.com) - 領先的中國醫學運營服務供應商雲康集團有限公司（「雲康」或「集團」；股份代號：2325）公佈截至2024年12月31日止年度（「報告期」）之全年業績。本年度，集團堅定執行「深度服務、精益運營」的總體經營方針，以創新促進發展，深化「政產學研醫用」一體化協同，加快「AI+醫療」數智化應用，持續加強精細化管理，降本增效，展現出強大的經營韌性。2024年，由於宏觀環境變化、行業競爭加劇以及集團戰略性優化客戶結構和產品結構等因素，短暫影響了集團的業績表現，但集團依託以客戶為中心的創新協同發展體系，在產品及模式創新、「AI+醫療」數智化等方面取得了突破。醫聯體共建業務持續成為集團第一大業務板塊，佔總收益的53.0%，較上年同期提升4.7個百分點；另外，感染性疾病檢測板塊的特色創新產品取得高速增長，為長期發展奠定基礎。報告期內，集團總收益達人民幣711.9百萬元。醫聯體診斷檢測健康發展，深度服務賦能客戶雲康一直致力於發展「以專業化為基礎、標準化為核心、數智化為手段、協同化為目標」的醫聯體共建創新服務模式。目前集團已為逾430家醫聯體現場診斷中心的超過1,500家醫聯體合作醫療機構，提供滿足核心需求的醫學技術服務解決方案，通過與各地龍頭醫療機構緊密協同合作，在區域檢驗結果互認、助力醫院專科能力建設、提高分級診療效率、促進科研協作等方面綜合提升區域醫療診療水平，為廣大群眾提供更加優質、高效的診療服務。在中國積極推動醫療改革的方向下，報告期內，雲康通過與省級頭部醫院、各地區縣級總醫院建立醫聯體共建合作，積極推動醫聯體建設，作為鏈接區域檢驗中心與合作醫院的紐帶，不僅為客戶提供「3+N」腫瘤、感染、生殖遺傳及+N的技術體系支撐，還提供深度服務體系的支持，包括區域醫聯體診斷中心運營、新技術╱ 新產品導入、數字化專科建設服務、醫學冷鏈物流服務、質量控制服務以及供應鏈服務等，以深度服務更好地賦能醫院的需求和長期發展。聚焦「臨床需求」，醫檢聯合創新成效明顯集團始終秉持以「臨床需求」為導向的服務理念，構建了包括高通量測序、基因芯片、高敏PCR、蛋白質譜、細胞遺傳、數字遠程病理以及超微病理在內的一系列高新技術平台。報告期內，集團新增檢測項目近800項，可向臨床提供約3,800種檢測項目，年檢測標本量超千萬例。在精準診療方面，集團以高通量測序和蛋白質譜等前沿技術開展超過500項精準診斷服務，覆蓋感染性疾病、生殖遺傳、實體腫瘤、血液病和個性化用藥等五大學科領域。報告期內，集團重點建設開發感染、腫瘤、遺傳罕見病及個性化用藥等領域的58項新項目，為全國醫療機構提供更全面的精準診斷解決方案，推動精準醫學的普及與發展。報告期內，集團特檢項目收益同比有較大增長，佔集團整體收益比重近一步提升。集團首創性打造「醫檢聯合創新平台」，在集團業務開拓及提升產品競爭力方面，發揮了重要作用。通過不斷探索和實踐，集團與全國數十家頂級醫療機構合作開展醫檢聯合創新合作，累計成功開發出超過10項針對呼吸道感染、中樞神經系統感染等多領域的不同感染症候群檢測產品。「AI+醫療」數智化應用，領航行業潮頭集團已上線並持續升級十大數字化「雲」系統，覆蓋實驗室運行、銷售管理、人力資源、員工培訓、客戶服務等核心領域。同時，集團將AI技術融入集團「雲」系統，打造從「樣本採集」到「報告交付」的一站式智慧醫療診斷解決方案，全面應用於旗下醫學實驗室的多技術平台，以「互聯網+」與「精準診斷」為核心理念，打造了一系列智能化的診斷平台。截止報告期，集團自主研發並擁有全部知識產權的數字化IT平台 － 遠程病理會診平台，已覆蓋超過800項醫學檢測項目，助力全國近300家醫療機構提升病理診斷能力，惠及超過2億偏遠地區農村患者。在AI輔助診斷應用上，集團堅持「成熟一個引進一個」的策略，緊密跟隨行業發展趨勢，已成功引進了病理DNA多倍體AI輔助診斷、宮頸液基細胞AI輔助診斷、染色體AI分析等項目，診斷效率大幅提升，應用效果不斷顯現。報告期內，集團聚焦感染性疾病領域，開發了首款感染性數據產品－「雲康呼吸道病原體檢測陽性率分析報告」，並於2025年1月正式獲得數據產品等級證書並上架廣州數據交易所。這標誌著集團在數據合規交易領域邁出了里程碑式的一步，實現了數據價值的有效釋放。目前，集團已正式接入DeepSeek大模型，以期通過技術普惠化、服務精準化、管理智能化，實現醫療檢測與診斷的全面革新。「政產學研醫用」一體化協同發展，助力產業升級年內，集團以獨特的產業模式創新為基礎，與不同的機構合作，助力產業升級，其中包括：- 與溫州市甌海區人民政府、溫州醫科大學圍繞生物醫藥產業的核心領域，推進聯合創新轉化平台、公共服務平台、醫療大數據研究平台、區域診斷共享中心，以及創新人才實訓基地等多個關鍵項目的建設，促進科研成果的快速轉化與產業化應用；- 與復旦大學張江研究院攜手共建「協同創新轉化中心」，共同推動醫學診斷技術的創新與成果轉化；- 與中央財經大學大灣區（黃埔）研究院共同構建產教融合人才培養高地及產業聚集孵化平台。可持續發展戰略驅動長期價值在大力推進業務發展的同時，雲康始終將可持續發展作為企業核心戰略之一，致力於通過創新技術和深度服務推動醫療健康行業的綠色轉型。集團不僅在運營中積極踐行節能減排、資源循環利用等環保舉措，還開展慈善義診、惠民體檢及健康講座等公益活動，發揮專業優勢，回饋社會。未來，雲康還將在ESG領域繼續耕耘，再接再厲，並於環境政策及管理、範圍三排放、氣候管治、氣候績效指標、氣候情景分析、減碳目標、淨零排放承諾等方面持續施力，以實現經濟效益、環境效益及社會效益的共贏。未來展望國家政策持續推進優質醫療資源擴容下沉和區域均衡佈局，加快建設分級診療體系，推進緊密型醫聯體建設。而中國實驗室自建檢測方法（LDT）試點工作穩步推進並取得顯著進展，將為精準醫學發展帶來市場增量。此外，人工智能技術與衛生健康行業的深度結合，將成為細分行業數智化轉型升級的重要驅動力。展望未來，雲康將繼續以國家政策為導向，把握行業發展的最新機遇，同時持續強化臨床賦能價值，以客戶為中心不斷探索和深化「產品創新+模式創新」兩大新模式，讓醫學成果更好惠及居民。雲康集團有限公司（股份代號：2325）雲康集團是中國領先的醫學運營服務提供商，早於2008年雲康便開始面向各級醫療機構提供標準化的醫療診斷服務，通過利用自身專業的診斷能力以及覆蓋全國的醫聯體服務網絡，逐漸發展成為醫學運營服務的領先平台。雲康也是中國領先的醫聯體診斷服務供應商，提供涵蓋醫聯體診斷及診斷外包的全方位醫療健康服務。雲康向中國醫聯體內的合作醫院提供診斷檢測服務，通過現場診斷中心協助其提升臨床診斷能力。迄今為止，雲康已成功為來自全國430+現場診斷中心提供專業服務，截至2024年12月31日，雲康合作的醫院分佈於中國31個省市。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年3月31日 - (亞太商訊 via SeaPRwire.com) - 華泰證券3月28日公告，2024年公司實現營業收入人民幣（下同）542.85億元，歸屬於本公司股東的本年利潤153.51億元。公司宣佈每10股派息3.7元（含稅），2024年累計分紅46.94億元。2024年，華泰證券保持以客戶為中心、科技賦能財富管理和機構服務的戰略定力，積極把握資本市場深化改革和金融高水平開放的戰略機遇，依託一體化、全業務鏈協同，深化國際化戰略佈局，資產規模與盈利能力穩居行業頭部。切實服務科技創新 科創板、創業板IPO躋身行業首位資本市場對促進產業和科技創新具有獨特而重要的支撑作用。作為中介機構，公司始終以服務國家戰略為己任，致力於提供與科技創新、產業發展周期各階段相適應的全業務鏈服務。2012年至2024年末，本集團累計服務科技創新企業超過270家，總市值約9.47萬億元。公司聚焦企業全生命周期需求，構建覆蓋TMT、大健康、高端製造等核心產業的金融服務體系，提供IPO、併購重組、資產證券化等一體化解决方案。2024年，公司股權主承銷規模549億元，其中A股IPO主承銷規模85.38億元，排名行業第二，科創板、創業板IPO主承銷規模均躋身行業第一；全品種債券主承銷規模12,960億元，排名行業第三；公司擔任獨立財務顧問的審核類重組項目首次披露數和獲監管受理數均位列行業第一。私募股權投資領域新增投資項目中，國家級專精特新小巨人企業與專精特新中小企業的數量超過10家。縱深拓寬全球金融服務體系 新興市場佈局加速近年來，華泰證券國際業務有效應對境外市場複雜多變的衝擊，保持逆市穩進，參與打造一系列港美股明星項目，綜合實力穩居香港中資券商頭部，2024年公司港股IPO保薦家數位列行業第三、保薦承銷規模位列中資券商第三。伴隨中國企業的全球化佈局展業，公司對標國際一流投行深入推進業務板塊和業務能力的全球化，在中國內地及香港、美國、英國、新加坡等多地聯動的基礎上，積極拓展國際業務佈局。2024年，華泰金控（香港）登記為東京PRO-BOND市場主承銷商；華泰證券（美國）新獲美國納斯達克證券交易所有限承銷會員資格；華泰國際旗下子公司以中資券商身份，於越南證券市場監管機構成功獲批證券交易代碼。國際業務的高效開展需要全球視角下的技術平台支撑，公司積極推進境內外一體化的下一代交易系統建設，自主研發的全球交易平台（GTP）已正式投入運營，24小時連接中國香港、美國、英國、新加坡市場。機構業務平台行知全面升級華泰海外研究和海外站，以國際化視野、前瞻性思維提供海外研究產品。2024年研究所共出具海外研報587篇，同比增長96%，研究範圍涵蓋美國、歐洲、日本、東南亞等多個區域；截至2024年底，覆蓋的美股、日股、韓股總數同比增長65%。主動適應變化 科技牽引業務轉型升級2024年，證券行業發展邏輯深刻變化，華泰證券堅持以科技賦能業務轉型，用平台高效連接資產、客戶與產品，推動機構服務能力升級。FICC全球一體化交易平台（HEADS）、信用分析管理平台（CAMS）等核心交易平台持續迭代，强化定價與交易服務優勢，實現從規模增長向能力產品化的轉型。機構客戶服務競爭力顯著提升，公募保險客戶排名持續領先。截至2024年底，科創板股票做市數量達126隻，上市基金做市服務覆蓋589隻ETF基金，均居行業前列；港幣-人民幣雙櫃檯做市業務實現標的全覆蓋，成交量市佔率顯著提升，獲頒港交所「2024年最活躍莊家 - 人民幣櫃檯」獎項。依託大語言模型與金融中台，公司持續構建智能化服務體系。「漲樂財富通」深化AI應用，優化ETF投資工具，推動客戶規模和資產規模增長。2024年下半年，公司權益基金保有規模、非貨幣市場基金保有規模、股票型指數基金保有規模分別為1,202億元、1,666億元、1,087億元，均排名證券行業第二，並躋身基金代銷總榜前十。華泰柏瑞滬深300ETF規模近3,600億元，穩居滬深兩市非貨幣ETF市場第一。此外，公司成為首批「跨境理財通2.0」試點券商，拓展全球化配置服務。華泰證券不斷提升自身治理水平，積極踐行可持續發展理念，2024年MSCI ESG評級從AA級躍升至AAA級，連續兩年實現進階，達到全球投資銀行業最高評級。公司依託華泰公益基金會，在鄉村振興、教育醫療、生態環境保護等領域持續加大投入，通過「一個長江」生態環境保護項目支持徵集中國OECM（其他有效的區域保護措施）潛力案例，在聯合國生物多樣性公約COP16大會上發佈，展示中國社會多元力量支持可持續發展的雄心。憑藉務實專業的項目管理和規範高效的內部治理，華泰公益基金會2024年首次參與江蘇省社會組織等級評估即獲得5A的最高評級。 Copyright 2025 亞太商訊 via SeaPRwire.com.

HONG KONG, Mar 31, 2025 - (ACN Newswire via SeaPRwire.com) - Yunkang Group Limited ("Yunkang" or the "Group"; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the "Reporting Period"). During the year, the Group adhered to its overall business philosophy of “in-depth services and lean operations”, promoted development with innovation, deepened integrated collaboration among “government, industry, academy, research, medicine, application”, accelerated digital application of “AI + medical care”, continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience.In 2024, due to changes in the macro-environment, intensified competition in the industry as well as its strategic decision to optimize customer structure and product mix, the Group’s performance was temporarily affected. However, relying on its customer-oriented, innovative and coordinated development system, the Group achieved many breakthroughs in product innovation, model innovation, AI + medical digital intelligence and other aspects. The joint construction business with medical institution alliances remained its largest business segment, which accounted for 53.0% of the total revenue, representing an increase of 4.7 percentage points as compared to the same period of the previous year. In addition, featured products in the infection segment achieved rapid growth, laying a solid foundation for the segment’s long-term development. During the Reporting Period, the Group’s total revenue reached RMB711.9 million.Diagnostic testing for medical institution alliances was developing healthily In-depth service empowers customersYunkang is committed to developing an innovative service mode for joint construction of medical institution alliances with “professionalism as the foundation, standardization as the core, digital intelligence as the means, synergization as the goal”. At present, the Group is providing medical technical service solutions to over 1,500 medical institutions in collaboration with medical institution alliances at over 430 on-site diagnostic centers of the alliances to meet their core demands. Through close collaboration – mutual recognition of testing results – with leading regional medical institutions, the Group has helped improve overall regional medical and treatment levels, helping hospitals build specialty departments, improving the efficiency of hierarchical diagnosis and treatment, promoting scientific research and cooperation, etc., thereby providing the public with higher-quality and more efficient diagnosis and treatment services. Dedicated to vigorously driving medical reform in China, during the Reporting Period, Yunkang teamed up with leading provincial-level hospitals, and regional county-level general hospitals to jointly build medical institution alliances to actively promote the construction of medical institution alliances as the bridge that connects the regional testing centers and partner hospitals. Customers are provided with “3+N” tumor, infection, reproductive genetics and +N technical system support, and also support from the in-depth service system, including the operation of diagnostic centers under regional medical institution alliances, access to new technologies or new products, construction services for digital specialty departments, medical cold chain logistics services, quality control services and supply chain services, all in-depth services for empowering demand and the long-term development of hospitals.Focus on “clinical demands” Joint innovation for diagnostic testing achieved remarkable resultsAdhering to the “clinical demands”-oriented service concept, the Group has built a series of high-tech platforms, including high-throughput sequencing, gene chip, high-sensitivity PCR, protein spectrometry, cytogenetics, digital remote pathology, and ultra-micro pathology. During the Reporting Period, the Group introduced nearly 800 new testing items and provided about 3,800 clinical testing items, and more than 10 million specimens were tested for the year. In terms of precision diagnosis and treatment, the Group carried out more than 500 precision diagnosis services using cutting-edge technologies such as high-throughput sequencing, and protein spectrometry, covering five medical fields including infectious diseases, reproductive genetics, solid tumors, blood diseases, and personalized medicine. During the Reporting Period, the Group focused on the construction and development of 58 new items in such fields including infection, tumor, rare genetic diseases and personalized medicine, providing medical institutions nationwide with a more comprehensive range of precision diagnosis solutions to drive the embrace and development of precision medicine. During the Reporting Period, revenue from special testing items increased significantly year-on-year, accounting for a larger percentage of the Group’s overall revenue.The Group has a first-of-its-kind “joint innovation platform for diagnostic testing”, which has played a vital role in expanding its business and boosting competitiveness of its products. Constantly exploring and putting ideas into practice, the Group and dozens of top medical institutions across the country have pursued joint innovation for diagnostic testing and successfully developed more than 10 testing products for different infection syndromes in various fields such as respiratory tract infections and central nervous system infections.Digital application of “AI + medical care” leads the industryThe Group has launched and continuously upgraded its top 10 digital “cloud” systems, covering core areas such as laboratory operations, sales management, human resources, staff training, and customer services. At the same time, it has integrated AI technology into its “cloud” systems to create a one-stop intelligent medical diagnostic solution covering from “sample collection” to “report delivery”, which was comprehensively applied across its multi-technology platforms in medical laboratories, with the core concepts of “Internet+” and “precision diagnosis” to create a series of intelligent diagnostic platforms. In the Reporting Period, the Group’s self-developed digital IT platform with full intellectual property rights – the remote pathology consultation platform – covered over 800 medical testing items, assisting nearly 300 medical institutions nationwide in enhancing their pathology diagnostic capabilities and benefiting more than 200 million patients in rural areas.Regarding the application of AI-assisted diagnosis, the Group adheres to the strategy of “introducing one item once it is mature” and closely follows industry development trends. It has introduced items such as pathological DNA polyploid AI-assisted diagnosis, cervical liquid-based cell AI-assisted diagnosis, and chromosome AI analysis, all proven effective and have greatly enhanced diagnostic efficiency. During the Reporting Period, the Group focused on the field of infectious diseases and developed its first infectious disease data product, the “Yunkang Respiratory Pathogen Detection Positivity Rate Analysis Report”. The product officially obtained data product certification and was listed on the Guangzhou Data Exchange in January 2025, marking a milestone step for the Group in the field of compliant data transactions, effectively unlocking data value. Currently, having access to the DeepSeek large model, the Group aims to achieve comprehensive innovation in medical testing and diagnostics through inclusive technology, precision service and intelligent management.Collaborative and integrated development of “government, industry, academy, research, medicine, application” to facilitate industrial upgradeDuring the Year, the Group collaborated with various institutions to facilitate industrial upgrade based on a unique innovative industrial model, including:- Collaboration with The People’s Government of Ouhai, Wenzhou City and Wenzhou Medical University’s core areas in biomedical industry to promote construction of a number of key projects including a joint innovation and transformation platform, a public service platform, a medical big data research platform, a regional diagnostic sharing center and a training base for innovative talent, to the end of facilitating quick transformation of scientific research results for industrial applications;- Collaboration with The Zhangjiang Research Institute of Fudan University to jointly establish a “Collaborative Innovation and Transformation Center” to promote innovation and transformation of results of medical diagnostic technology application;- Collaboration with The Central University of Finance and Economics, Greater Bay Area Research Institute to jointly build an industry-education fusion talent cultivation highland and an industry aggregation and incubation platform.The strategy for sustainable development drives long-term valueWhile vigorously driving business development, Yunkang has consistently viewed sustainable development as a core strategy of the Group, committed to promoting the green transformation of the healthcare industry through innovative technologies and in-depth services. The Group engaged in environmental protection efforts such as energy conservation, emission reduction, and resource recycling in its operations, while also launched various charitable initiatives, including charitable clinical diagnostic activities, health checkup services for the well-being of the community, and health seminars, to give back to society by making use of its professional advantages. Looking ahead, Yunkang will continue to make progress in ESG and step up our efforts in such areas as environmental policy and management, Scope 3 emissions, climate governance, climate performance indicators, climate scenario analysis, carbon reduction targets, and net-zero emissions commitment, all of which will help us realize economic, environmental and social benefits.Future prospectsChina has continued to promote expansion and downward penetration of the country’s high-quality medical resources, fostering a balanced regional layout and stepping up the construction of a hierarchical diagnosis and treatment system, conducive to establishing close-knit medical institution alliances. China’s Laboratory Developed Testing methods (LDT) pilots have steady and notable progress, leading to market growth for precision medicine development. In addition, in-depth integration of AI technology with the healthcare industry will become an important driving force for fine industry segments to embark on digital intelligence transformation and upgrade. Looking ahead, Yunkang will continue to align with national policies, seize the latest industry development opportunities, and continue to strengthen clinical-empowered value, and constantly explore and deepen the two new “product innovation + model innovation” model with customers in mind and to ensure residents can better benefit from its medical achievements.Yunkang Group Limited（Stock Code：2325）Yunkang Group is a leading medical operation service provider in China, which started to provide standardized medical diagnostic services to medical institutions at all levels as early as 2008. Leveraging its own professional diagnostic capabilities and the nationwide service network of integrated healthcare systems, Yunkang has gradually grown to become a medical operation service platform. Meanwhile, Yunkang is a medical operation service provider in China offering a full suite of diagnostic testing services which are diagnostic outsourcing services and diagnostic testing services for medical institution alliances. Yunkang provides diagnostic services through on-site diagnostic centers to collaborative hospitals in the integrated healthcare systems in China and assists them in improving their clinical diagnosis capabilities through co-developing diagnostic centers. As of today, Yunkang has successfully provided professional services to 430+ on-site diagnostic centers. As of December 31, 2024, the hospitals we collaborated with were located across 31 provinces and municipalities in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 4, 2025 - (ACN Newswire via SeaPRwire.com) - Connect Marketplace Hong Kong (CMHK) successfully concluded its preview event in APAC in 2025, marking a significant milestone in fostering business collaboration within the MICE industry. Held from 19-21 March 2025, the event successfully brought together over 4,000 industry professionals, along with more than 60 exhibitors from over 30 countries and regions. It focused on creating an invaluable platform for networking and business development.Margaret Ma Connolly, president and CEO of Informa Markets in Asia, highlighted the event’s role in driving transformation within the MICE industry. “The launch of Connect Marketplace Hong Kong is more than just a new event. It's a testament to our belief in Hong Kong as the ultimate MICE destination. Here at Connect Marketplace Hong Kong, we’re not just discussing the future of business events – we’re actively shaping it, fostering connections that transcend borders and drive economic growth across Asia and beyond” she said.Connect Marketplace Hong Kong excelled as a premier platform for business collaboration, featuring the Hosted Buyer Programme, which brought together around 450 international decision-makers and facilitated close to 1,300 business organised through its innovative one-on-one meeting initiatives.Additionally, conference sessions and forums addressed key industry topics, from sustainability to cutting edge MICE solutions. A series of networking opportunities, including Horse Racing Night, Gala Dinner and a Familiarization Trip to Macau further strengthened interactions among global industry players.Janice Lee, Senior Portfolio Director of Connect Marketplace Hong Kong, expressed excitement for future growth: “This is a remarkable achievement! I have witnessed the spirit of Informa unfold over four months of hard work, culminating in around 4,000 attendees at the show. This success gives us great confidence as we look ahead to the next edition of CMHK in 2026.” The next edition of Connect Marketplace Hong Kong is scheduled for 18-19 March 2026.About Informa MarketsInforma Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.For media enquiries, please contact: cheenie.so@informa.com Copyright 2025 ACN Newswire via SeaPRwire.com.

HIGHLIGHTS:- During the Reporting Period, the Group’s gross billings amounted to approximately RMB3,505.9 million, representing an increase of approximately 49.3% from approximately RMB2,347.7 million for the Corresponding Period.- The total revenue of the Group was approximately RMB2,306.0 million, representing an increase of approximately 17.3% compared to approximately RMB1,965.4 million for the Corresponding Period.- The profit attributable to Shareholders of the Group was approximately RMB272.4 million, representing an increase of approximately 42.8% from approximately RMB190.7 million for the Corresponding Period.- The Group’s operating cash flow (net inflow) was approximately RMB1,627.8 million, representing an increase of approximately 266.6% as compared to approximately RMB444.0 million for the Corresponding Period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD148.0 million for the year ended December 31, 2024, representing HKD0.33 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Apr 4, 2025 - (JCN Newswire via SeaPRwire.com) - 28 March, JF SmartInvest Holdings Ltd(the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2024 (the “Reporting Period”). During the Reporting Period, the Company realized a revenue of approximately RMB2,306.0 million, representing a growth of approximately 17.3% from the Corresponding Period. Profit attributable to Shareholders amounted to approximately RMB272.4 million, representing an increase of 42.8% over the Corresponding Period. In addition, our operating cash flow was strong. We had a net inflow of approximately RMB1,627.8 million which represented a significant year-on-year growth of 266.6%, fully demonstrating the effective strategy execution and high market adaptability of the Company.Developed a multi-dimensional product structure to promote business and revenue diversificationDuring the Reporting Period, on top of integrating and improving our existing products, we launched the industry’s first-ever stock learning machine and enriched our small-amount series product matrix for the promotion of revenue diversification. We have formed four main product lines currently, namely “Stock Navigator Series and Super Investor” , “Enjoy-Stock Pad”, “Jiuyao Stocks” and “SmartInvest App” (App). We aim to serve a wider spectrum of customers in a more effective manner by capitalizing on the synergies of these product lines.In order to meet users’ needs, we launched the first “Enjoy-Stock Pad (Starter Edition)” in July to fill the market gap for professional stock learning products. The Company expected that the launch of this product would create a dedicated learning platform for investors, actively fulfil corporate social responsibilities and deepen the inclusive financial education practice. In the meantime, we launched nearly 30 lightweight products to achieve product scalability and standardization, which allowed us to meet the diverse users’ needs and fully explore long-tail customers. During the Reporting Period, our small-amount series products were used by our subscriber customers for more than 2.203 million times.Adherence to pursuing “technological research + investment research” dual-driver strategy, deepening AI technology for full empowerment for the Company’s business and practical applicationImplementing our “technology + investment research” dual-driver strategy, we further increased our R&D investment, explored the empowerment and application of AI and other frontier technologies to the Company’s product offerings, business operations and operational management. With focus on the “buyer-side investment advisory” service, we strengthened our “1+N” investment research system to fully penetrate our investment research into businesses and processes, so as to professionally support our customers in creating long-term value.We continuously strengthened our R&D capabilities and investment: During the Reporting Period, we invested approximately RMB319 million in R&D activities, representing an increase of 10.9% over the Corresponding Period. Such R&D investment accounted for approximately 13.8% of the Company’s total revenue. In addition, as of the end of the Reporting Period, we had 136 software copyrights and patents on product features, big data and AI, that was 52 more than last year. What is noteworthy is that during the Reporting Period, we became a member of the Chinese Association for Artificial Intelligence (CAAI), signifying that the Company has been recognized for its core AI R&D technologies and achievements in the financial sector.We explored the all-round empowerment of AI and other frontier technologies to the Company’s product offerings, business operations and operational management. In terms of empowering our product offerings, we launched “FinSphere Agent”, a new-generation conversational stock investing assistant, and “FinSphere Report”, an intelligent investment research product. They provide deep-thinking intelligent conversational investment advisory services and intelligent research report generation and explanation services. We continuously upgraded our digital investment robo-advisor “Jiu Ge”, served approximately 472,000 customers, with total services reaching 32.407 million times, during the Reporting Period. In terms of empowering our business operations, we deployed our “AI Marketing Partners” and “AI Live Replay Summaries” which enabled us to achieve full-process coverage of text generation and pitch recommendations that doubled our communication efficiency. In terms of empowering our compliance management: The Company developed the intelligent compliance management solution 3.0, with which, our “AI Monitoring Officer” has conducted approximately 1.6 billion monitoring tasks and our “AI Inspection Officer” has assisted in over 10 million review tasks, achieving a coverage rate of 98%.We focused on “buyer-side investment advisory” and emphasized the application of our investment research. In the single month of December, our professional stock review programs output an average of approximately 22 shows per day, with a total duration of nearly 13 hours; we engaged active interactions with investors and answered their questions. The average number of inquiries per day exceeded 2,500. Our JF Financial Research Institute has designed more than 218 sets of self-developed signature courses, with a total of more than 1,300 sessions and a total of over 12,000 minutes, further improving the system of providing courses on our Stock Learning Machine.Establishment of quality traffic system to achieve precise expansion of new customer baseWe established quality traffic system and continued to expand our presence on platforms. During the Reporting Period, apart from our established presence on Douyin and WeChat Channels, we explored Kuai and tapped into platforms such as Xiaohongshu and Bilibili, to achieve high accessibility to customers, increase our brand exposure, optimize our live broadcast efficiency and enhance viewers’ experience through short video + live broadcast approach. The live broadcasts lasted over 49,800 hours cumulatively with 26,500 sessions, representing a growth of over 110% from the Corresponding Period. During the Reporting Period, we operated 152 new MCN accounts on different internet platforms. As of December 31, 2024, we had 526 MCN accounts and attracted approximately 50.05 million followers, as compared to approximately 11.15 million followers in the Corresponding Period.At the same period, we actively promoted popular investor education and enhanced brand influence. At the National Investor Protection Publicity Day on May 15, we organized the “Shareholders Are Here” event jointly with Everbright Securities to attract investors’ participation in the education on rational investing through short videos and live broadcasts on all of the Company’s platforms, together with the active promotion by traditional media such as Hubei TV and China Business Network (CBN). As of December 31, 2024, we have exclusively sponsored CBN’s live broadcast of the Berkshire Hathaway Annual Shareholders Meeting for the fifth consecutive year. We produced the live broadcast program “Buffett and Seven Lunches”, which recorded a total online viewership of nearly 227 million.Business outlookThe chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, Mr. Chen Wenbin said: "We will adhere to our principles of rational investing, value investing and long-term investing to help customers induce right investing concepts, practice investor education, fulfil corporate social responsibility and commit ourselves to promoting healthy development of the capital market in the long run. Looking forward to 2025, we, as a next-generation stock investing assistant, will continue to strengthen our competitiveness, solidify our market leadership and strive to make investing and wealth management easier yet more professional, and enhance the happiness of investing and wealth management. "About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, stock learning machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2025 ACN Newswire via SeaPRwire.com.

Kuala Lumpur/Bangkok/Singapore , Apr 3, 2025 - (ACN Newswire via SeaPRwire.com) - India is emerging as the world’s next manufacturing giant—yet global corporations still stumble at the entrance. Despite its $7.5 trillion growth trajectory, cost advantages, and policy incentives, there are still several obstacles in the way of building a long-lasting presence in India. A recent whitepaper titled “Why Do Global Manufacturers Struggle with India Market Entry” offers a data-driven blueprint for overcoming regulatory, supply chain, and regulatory obstacles in one of the world’s complex but most promising economies.Regional companies aiming to expand into India can find a powerful roadmap in SRKay Consulting Group’s latest release, “Why Do Global Manufacturers Struggle with India Market Entry” This comprehensive publication outlines the key challenges that often derail even the most experienced players—including regulatory red tape, infrastructure hurdles, intellectual property risks, pricing pressures, and workforce acquisition difficulties.The report dives deep into the root causes behind these obstacles, from fragmented supply chains to complex compliance landscapes, and presents a structured, four-pillar India entry strategy. Covering insights across seven key sectors, it serves as an essential guide for manufacturers seeking to build a resilient and scalable presence in the Indian market.Highlights & Strategic Takeaways:A Proven India Market Entry Framework: A four-pillar approach covering research, business setup, supply chain localisation, and long-term growth.Real Success Stories: What global giants like Apple, Hyundai, and IKEA won in India by adapting to local demand and operational realities.Insights for Emerging Market Entrants: UAE and Malaysia-based companies prioritise India’s growth and competitive costs, but face workforce, regulatory, and IP-related hurdles.Digital & Trade Enablers: How UPI, ONDC, and Free Trade Agreements (like CEPA and ECTA) are creating new competitive advantages for manufacturers.“India is not just a big market—it’s a complex one. For Southeast Asian companies, entering India without the right regulatory, supply chain, and cultural game plan is risky. This whitepaper is our answer to help them succeed,” said Alok Kumar, Founder & Managing DirectorThis whitepaper is an essential resource for business strategists assessing market viability or C-suite executives considering expansion to confidently and clearly navigate the India opportunity.Download the Whitepaper NowWhy Do Global Manufacturers Struggle with India Market EntryAbout SRKay Consulting GroupSRKay Consulting Group is a global consulting firm that helps companies expand into emerging markets like India through data-led strategies, market entry advisory, and operational consulting. With deep expertise in regulatory compliance, digital infrastructure, and supply chain localization, SRKay is the trusted partner for Southeast Asian firms entering India.For expert consultation and partnership opportunities, connect with:Komaldeep KaurEmail: Komal@mianext.com Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年4月3日 - (亞太商訊 via SeaPRwire.com) - 3月28日,亞太商旅會展匯Connect Marketplace Hong Kong 於 2025年3月19日至21日在香港亞洲國際博覽館圓滿舉行。展會匯聚全球超過30個國家及地區行業精英，共60多家參展企業，吸引逾4,000位業界專業人士參與。展會致力打造高效商務平台，促進會展及獎勵旅遊業的交流與合作，為與會者創造顯著商業價值。亞洲英富曼會展有限公司 (Informa Markets)亞洲區總裁兼首席執行官馬穎（Margaret Ma Connolly）表示：「亞太商旅會展匯Connect Marketplace Hong Kong的啟航不僅意味著一個新展會的誕生，更體現了我們對香港作為亞太地區會展及獎勵旅遊業理想樞紐的堅定信心。 我們不僅在此探討行業未來，更在這裡積極推動行業發展，構築跨越國界的橋樑，助力亞洲乃至全球會展及獎勵旅遊業實現真正的增長與繁榮。」作為行業領先的商務對接平台，本屆展會特設特邀買家（Hosted Buyer）配對計劃，吸引約450名全球重要決策者參與。展會期間共促成近1,300 場高效的一對一商務配對會議，為參展商和買家提供了精準對接的絕佳機會。此外，展會期間還舉辦了多場高端行業論壇，深入探討會展及獎勵旅遊業的前沿趨勢及可持續發展的解決方案。 同時展會更策劃了「賽馬之夜」、「尊貴晚宴」及「澳門考察之旅」等一系列交流活動，進一步促進全球參會者之間的緊密聯繫與互動。亞太商旅會展匯Connect Marketplace Hong Kong高級項目總監李佩儀（Janice Lee）表示：「在短短四個月的籌備時間，通過團隊的協同努力，展會成功吸引了4,000多位來自會展及獎勵旅遊業的專業買家，實現了前所未有的成功！我們對來年的展會充滿信心，期待能再創佳績！」下一屆亞太商旅會展匯Connect Marketplace Hong Kong將於2026年3月18日至19日舉行，敬請期待！關於亞洲英富曼會展有限公司亞洲英富曼會展有限公司 (Informa Markets) 旨在為各行各業和專業市場，提供交易、創新和發展平台。業務包括550多個國際B2B活動和品牌，涵蓋多個領域，包括醫療、保健與製藥，基礎設施，建築及房地產，時尚服飾，酒店、食品與飲料，以及健康與營養等。通過舉辦面對面會展，提供專業數據和可執行數據解決方案，為全球客戶和合作夥伴提供參與、體驗和達成交易的機會。作為全球領先的會展主辦方，我們為各種各樣的貿易行業注入發展動力，釋放機遇 ，為其蓬勃發展助一臂之力。欲了解更多信息，請瀏覽www.informamarkets.com。傳媒查詢，請聯絡：cheenie.so@informa.com Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年4月3日 - (亞太商訊 via SeaPRwire.com) - 香港領先的品牌保健品營銷商及分銷商健倍苗苗（保健）有限公司 （「健倍苗苗」；股份代號：2161，連同其附屬公司統稱「集團」）今天公布已完成收購天喜堂藥廠有限公司（「天喜堂」）90%股權，總代價為171.0百萬港元。天喜堂現正式成為健倍苗苗的非全資附屬公司。引入信譽悠久品牌 強化產品組合天喜堂旗艦產品「天喜堂天喜丸」歷史悠久，在香港及中國内地（尤其廣東省）享有極高的品牌知名度。該產品配方獨特，專為調節女性生理周期、促進生殖健康及增強血液循環以提升氣色而設，深受女性消費者信賴，被廣泛視為婦科健康的可靠良方。集團看好其獨特的市場定位及長期增長潛力，是次收購將有效強化集團品牌中藥產品組合的戰略佈局。釋放增長潛力及協同效應是次收購為擴展集團的品牌中藥組合，並加快其增長策略，提供了一個極佳的機會。通過將此一標誌性品牌納入現有產品線，集團可充分把握市場增長機遇，滿足消費者對全人健康解決方案日益增長的需求。為充分發揮品牌潛力，集團計劃開展全面的市場推廣活動，憑藉其成功的品牌管理及年青化經驗，提升消費者認知度及參與度。同時，集團將擴展分銷網絡，把握新市場機遇及拓展新的客戶群。透過收購業務的互補優勢，是次收購預期可帶來顯著的協同效應，符合集團收購資產及業務之策略，有助強化其長遠願景及提升股東價值。品牌年青化的成功經驗集團對傳統中藥品牌年輕化擁有豐富經驗，成功將將經典產品轉化為市場領先品牌。旗下標誌性品牌包括腸胃中成藥市場的領導品牌「保濟丸」、家喻戶曉的止痛退燒藥品牌「何濟公」、以及透過融合香港懷舊情懷與創意廣告，成功塑造全新形象的傳統中藥油品牌「飛鷹活絡油」。集團透過策略性品牌重塑、全渠道拓展及數碼驅動的消費者互動策略，成功將傳統品牌轉型為同時深受忠實客戶及年輕一代青睞的現代保健解決方案。健倍苗苗將為「天喜堂天喜丸」這個信譽卓著的品牌注入新動力，進一步擴大其市場影響力。健倍苗苗行政總裁黃一偉先生表示：「收購天喜堂是鞏固我們在品牌中藥板塊領導地位的關鍵舉措。憑藉其深厚的品牌底蘊及廣泛的市場認可度，『天喜堂天喜丸』將為我們的產品組合帶來高度互補的協同效應。憑藉豐富的品牌重塑經驗，集團有信心全面釋放該品牌的市場增長潛力，為股東創造長遠價值。」有關健倍苗苗（保健）有限公司 （股份代號：2161）健倍苗苗是設於香港的品牌醫療保健品推廣及分銷公司，產品據點遍及大中華、東南亞及其他選定國家。集團擁有豐富的行銷專業知識並具備深厚的製藥背景，秉承產品功效和品質至上的優良傳統，在行業內定位獨特，致力於滿足消費者的保健需要。作為本地領先的品牌醫療保健品運營商，集團擁有一廣泛系列品牌醫療保健品，包括品牌藥、品牌中藥及健康保健品，其中包括「保濟丸」、「何濟公止痛退熱散」、「天喜堂天喜丸」、「飛鷹活絡油」、「唐太宗活絡油」、「十靈油」、「鎮痛霸祛風活絡油」、「德國秀碧除疤膏」及「美德瑪寶兒除疤啫喱」等家喻戶曉的傳統品牌。而自2021年 5月27日，集團獲納入 MSCI 香港微型股指數成份股。有關集團詳情，請瀏覽：www.jbmhealthcare.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

摘要：- 報告期內，本集團總訂單金額約為人民幣3,505.9百萬元，較同期的約人民幣2,347.7百萬元增加約49.3%。- 總收益約為人民幣2,306.0百萬元，較同期的約人民幣1,965.4百萬元增加約17.3%。- 股東應佔溢利約為人民幣272.4百萬元，較同期的約人民幣190.7百萬元增加約42.8%。香港, 2025年4月3日 - (亞太商訊 via SeaPRwire.com) - 3月28日，九方智投控股有限公司（「九方智投控股」或「公司」；及其附屬公司統稱「本集團」或「我們」）欣然宣佈截至2024年12月31日止年度（「2024年」或「報告期內」）之綜合年度業績。報告期內，公司實現收益約人民幣2,306.0百萬元，較同期增長約17.3%；股東應佔溢利約為人民幣272.4百萬元，較同期增加約42.8%；此外，經營性現金流表現強勁，淨流入額約為人民幣1,627.8百萬元，同比大幅增長約266.6%，充分彰顯公司戰略執行成效與市場適應能力。構建多維產品體系 推動業務與收入多元化報告期間，在整合完善現有產品基礎上，本集團推出業內首款股票學習機，豐富小額系列產品矩陣，推動收入多元化。目前已形成「股道領航系列和超級投資家」、「易知股道－九方智投股票學習機」、「九爻股」、「九方智投App」的四大產品線，通過協同效應，旨在更有效地服務於更廣泛的客戶群體。公司以用戶需求為出發點，於7月首發「易知股道－九方智投股票學習機啟航版」，推出行業首款股票學習機填補市場空白，希望通過該產品，為投資者打造專屬學習平台，積極踐行企業社會責任，深化金融普惠教育實踐，報告期內，人均每日使用時長已超2小時。同時推出近30款輕量級產品，以實現產品規模化和標準化，充分挖掘長尾客戶，匹配用戶多樣化需求，報告期內，小額系列產品在期客戶使用次數超220.3萬。堅持「科技+投研」雙輪驅動戰略 持續深化AI全方位賦能與落地我們秉持「科技+投研」雙輪驅動策略，持續加大研發投入，探索AI等領先技術對公司產品服務、業務運營、經營管理的賦能和應用，堅守「買方投顧」，強化「1+N」投研體系，實現投研全面滲透業務及流程，為客戶長期價值創造提供專業支撐。研發實力與投入持續增強，報告期內，研發投入約人民幣319百萬元，較同期增長10.9%，研發投入佔公司總收益約13.8%。並且，截至報告期末，擁有產品功能、大數據、人工智慧等方面軟件著作權、專利136件，同比新增52件。值得關注的是，報告期內，我們成為中國人工智能學會(CAAI)成員單位，標誌公司在金融領域核心人工智能研發技術和成果得到認可。我們探索AI對公司產品服務、業務運營、經營管理的全方面賦能。在產品服務方面，推出新一代股票投資對話助手「九方靈犀」及智能投研產品「九方智研」，提供深度思考模式的智能投顧對話服務及智能研報生成和解讀服務；智能投顧數字人「九哥」不斷迭代升級，報告期間服務客戶約47.2萬，累計服務達3,240.7萬次。在業務運營方面，部署「AI營銷夥伴」、「AI直播回放總結」，實現文本生成、話術推薦全流程覆蓋，溝通效率翻倍。在合規管理方面，公司構建智能合規管理解決方案3.0，「AI監測官」累計監測約16億次、「AI巡查官」輔助審核超1,000萬次，覆蓋率達98%。我們堅持「買方投顧」，注重投研應用，僅12月期間，專業股票解復盤節目日均輸出約22檔，總時長達近13小時；積極與投資者互動、答疑解惑，日均諮詢量超過2,500條；九方金融研究所自研精品課程超過218套，累計課程約1,300節，總計超過12,000分鐘，進一步完善了股票學習機課程體系。打造優質流量體系 精準拓展新客戶群我們打造優質流量體系，持續拓寬平台陣地。本報告期，在抖音、視頻號基礎上，我們探索快手，佈局小紅書、B站等平台，利用短視頻+直播實現客戶高頻觸達，擴大品牌曝光，並優化直播效率、提升觀眾體驗，累計直播時長超過49,800小時，場次達約26,500場，均較同期增長超過110%；我們報告期內在不同互聯網平台上增加152個營運的MCN賬戶，截至2024年12月31日達到526個賬戶，吸引到約5,005萬名追隨者，較同期增加約1,115萬名追隨者。與此同時，我們積極普及投教，提升品牌影響。「5-15全國投資者保護宣傳日」期間，我們聯合光大證券開展《股東來了》活動，通過短視頻、直播等形式在公司所有平台，湖北衛視、第一財經等傳統媒體積極宣傳，吸引公眾參與理性投資教育。截至2024年12月31日，我們已連續第5次獨家冠名第一財經巴菲特股東大會直播，打造《巴菲特與七頓午餐》欄目，本次直播全網總流量近2.27億。展望未來九方智投控股董事會主席及首席執行官陳文彬先生表示：「我們貫徹理性投資、價值投資和長期投資理念，幫助客戶構建正確投資觀，踐行投資者教育，履行企業社會責任，更以推動資本市場長期健康發展為己任。展望2025年，作為新一代股票投資助手，我們將持續強化競爭力，穩固市場領先地位，致力於讓投資理財更簡單、更專業，提升投資理財的幸福感。」關於九方智投控股有限公司九方智投控股有限公司作為新一代股票投資助手，面向廣大個人投資者提供股票投資工具、證券投資顧問、投資者教育等服務，相繼推出股票行情軟件、股票學習機、股道領航、超級投資家、九爻股等產品。該公司通過"科技＋投研"模式，基於人工智能（AI）與大数据技術研發九方智能投顧數字人、九方靈犀、九方智研等AI產品，實現行業創新實踐與場景應用。如有垂詢，請聯絡：金融公關（香港）有限公司電郵：ir@financialpr.hk電話：852 2610 0846傳真：852 2610 0842 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港, 2025年4月3日 - (亞太商訊 via SeaPRwire.com) - AEON信貸財務（亞洲）有限公司（「AEON信貸財務」或「集團」；股份代號：00900）今天公布截至二零二五年二月二十八日止年度之全年業績（「二零二四/二五財年」或「報告年度」）。於報告年度，集團收入較上一年度增長8.4%至1,759,300,000港元，主要得益於集團實施多項營銷計劃，有效刺激信用卡消費，促使信用卡及私人貸款應收款項穩定增長。收入增長亦歸因於費用及佣金收入增長10.4%，這得益於信用卡收單業務交易量的提升，以及保險中介業務新保險產品的推出。隨著營運效率提升，成本對收入比率從截至二零二四年二月二十九日止年度（「二零二三/二四財年」或「上一年度」）的46.9%微降至46.6%，在營運層面上及未計入虧損及減值準備前，營運溢利上升9.1%至881,200,000港元。二零二四/二五財年稅後溢利增長2.1%至400,500,000港元。董事會建議派末期股息每股25.0港仙（二零二三/二四財年：每股24.0港仙），二零二四/二五財年全年股息為每股49.0港仙，派付股息比率為51.2%。因應市場復甦步伐較預期緩慢，集團於二零二四/二五財年優先考慮穩定銷售和應收款項增長，專注於打造著重創造收入、增長和韌性的高質量客戶貸款組合。相比上一年度，集團整體銷售額再創新高，持續增長10.5%。截至二零二五年二月二十八日，客戶貸款及應收款項餘額與二零二四年二月二十九日的餘額相比增加了5.3%。此外，集團於報告年度内獲得由九家地區及本地銀行組成的銀團所提供三億港元可持續發展表現掛鈎借款，進一步彰顯集團將可持續發展理念融入其業務營運的堅定承諾。在市場推廣方面，集團與多個業務夥伴合作開展具針對性的營銷及推廣活動，向目標客群更有效地宣傳精心開發的產品及服務之競爭優勢。此外，為實現分行網絡多元化並滿足客戶對面對面諮詢服務日益增長的需求，集團繼續整合及擴充其分行網絡，包括於二零二四年六月開設沙田新分行。客戶體驗方面，升級後的信貸申請處理平台促進了「AEON 香港」手機應用程式（「手機應用程式」）內虛擬信用卡功能的推出，客戶可在信用卡獲批及啟動後立即進行購物。集團亦持續將營運數碼轉型列為重點工作，其中包括強化客服平台以提升客戶互動回應效率。在信貸管理方面，加強後的信貸監控模型納入了更新的客戶信貸使用指標，改善了信貸風險分配，促進和更精準地利用、監控和控制客戶組合的信貸風險。與此同時，為進一步鞏固集團的科技基礎，集團已成功將核心資料中心遷至將軍澳，優先考慮運作時間、容錯能力及成本效益，該中心亦符合國際認可的綠色建築認證標準。此外，集團已完成改造綜合核心營運系統平台。此等改進措施為未來產品推出及系統升級奠定了更堅實的資訊科技基礎架構。展望二零二五年，預計本地消費市場將繼續逐步復甦，集團將優先透過海外和線上消費來實現銷售額和應收款項的增長。與此同時，集團將改進信貸評估和監測方法，以保持可持續的資產質素組合並加快審批速度。集團一直致力於創新與科技，並始終為客戶提供無與倫比的使用體驗。未來一年，集團計劃開發及實施全新一體化的積分回贈平台，以簡化積分管理流程。新的積分平台允許客戶在單一平台上無縫管理和累積從 AEON 信用卡和其他參與商戶獲得的積分，以確保易於使用。作為香港負責任的消費金融服務供應商，集團始終致力於將可持續發展理念融入其營運，並將繼續推廣可持續和數碼化的產品和服務，包括即將推出、支持顧客轉向低碳生活方式的貸款產品。此外，隨著非接觸式流動支付在香港的普及，集團將進一步投資開發虛擬卡功能。AEON信貸財務董事總經理魏愛國先生表示：「儘管經營環境充滿挑戰，我們欣然於二零二四/二五財政實現穩健增長，為長期可持續發展奠定堅實基礎。適逢AEON信貸財務成立三十五週年，我們始終致力提供以客為本的卓越信用卡服務。集團目標透過推出創新及客製化產品擴大客戶群，並於快速發展的消費金融市場中把握新的增長機遇。憑藉集團強大的流動性和穩健的資產負債表，我們具備充分優勢維持增長動能，推動未來業務持續成功。」關於AEON信貸財務（亞洲）有限公司（股份代號： 00900）AEON信貸財務（亞洲）有限公司為AEON Financial Service Co., Ltd.之附屬公司（東京證券交易所代號：8570）及AEON集團旗下公司，成立於1987年，並於1995年在香港聯合交易所有限公司主板上市。集團主要從事金融業務，包括於香港簽發信用卡及提供私人貸款、信用卡付款處理服務、保險中介業務，以及於中國內地從事小額金融業務。詳情請瀏覽公司網址：www.aeon.com.hk。 Copyright 2025 亞太商訊 via SeaPRwire.com.